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Findings from early percutaneous tricuspid intervention trials have shown that the severity
of tricuspid regurgitation (TR) far exceeded the current definition of severe TR. Also, the
improvement in the amount of TR following tricuspid intervention is not accounted for by
the current definition of TR as different degrees of severity at the severe end was grouped
under the same umbrella term of “severe.” There has been a recent call to expand the
TR grading system, encompassing two more grades, namely “massive” and “torrential”
TR, in the order of increasing severity. This seems appropriate as the patients enrolled
in tricuspid intervention trials were found to have TR severity up to 2 grades above the
current severe thresholds of effective regurgitant orifice area (EROA) 40 mm2, regurgitant
volume (R Vol) 45ml and vena contracta (VC) width 7mm. The proposed grade of
“massive” is defined by EROA 60–79 mm2, R Vol 60–74ml and VC 14–20mm, while
“torrential” is defined by EROA ≥80 mm2, R Vol ≥75ml, and VC ≥21mm. The grading
of TR requires a comprehensive, multi-parametric approach. In particular, quantitative
assessment of TR should be performed in patients who require serial monitoring and
quantification of treatment effect.
Keywords: tricuspid regurgitation grading, massive tricuspid regurgitation, torrential tricuspid regurgitation,
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INTRODUCTION
The tricuspid valve has often been labeled the forgotten valve, due to the lack of attention it
received compared to its counterparts such as the mitral or aortic valve (1). Research interests
and advancement in therapy, most notably percutaneous valve intervention for years seems to
elude the tricuspid valve. In recent years, the tide appears to be turning. We witnessed a rise in
interest and developmental breakthroughs in the treatment of functional or secondary tricuspid
regurgitation (TR). The movement is both appropriate and timely as functional TR is a common
but often-overlooked clinical problem. Severe TR is associated with increased morbidity and
mortality (2, 3). Despite the poor outcomes, the number of patients with severe TR undergoing
tricuspid valve surgery was dismal. Approximately 1.6 million patients in the United States live
with moderate to severe TR and there are <8,000 tricuspid surgery performed annually (4, 5).
The overwhelming majority of tricuspid valve surgery was performed during concomitant left-
sided valve surgery (6). Among patients who underwent left-sided valve surgery, 37% eventually
developed severe TR following rheumaticmitral valve replacement and 74% hadmoderate to severe
TR 3 years after ischemic mitral repair surgery (7, 8). This not only speaks volume of the unmet
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need for TR treatment, but also illustrates the treatment difficulty
in patients with previous left-sided heart surgery who need
downstream TR intervention, either in the form of redo surgery
or percutaneous therapy. Last but not least, it highlights the
importance of comprehensive andmethodical echocardiographic
assessment prior to or following any valve surgery.
ECHOCARDIOGRAPHIC ASSESSMENT OF
TR
Echocardiography is the imaging modality of choice to assess
TR severity and in turn, help to guide decision for treatment.
The guideline-recommended echocardiographic assessment of
TR is, however, not without its challenges. It involves a
multi-parametric approach and calls for qualitative, semi-
quantitative, and quantitative evaluation (9). Qualitative and
semi-quantitative assessment are relatively straightforward and
intuitive as they do not require multi-step calculations as
quantitative approach does. As a result, many clinicians often
adopt the qualitative or semi-quantitative approach, which give
rise to two problems. First, it renders most comparisons, either
serially over time or between patients difficult due to the lack
of precision and standardization. Second, it is prone to under-
estimation of the regurgitant severity.
Traditionally, TR is graded into mild, moderate, and
severe, following the severity grading conventions that also
apply to mitral, aortic, and pulmonary valves. Severe TR is
defined quantitatively as an effective regurgitant orifice area
(EROA) of ≥40 mm2 and a regurgitant volume of ≥45ml
according to both the European Association of Cardiovascular
Imaging (EACVI) and American Society of Echocardiography
(ASE) recommendations (9, 10). In particular, the EACVI
recommendations made provision for massive TR. Massive TR
is referred to as TR that is beyond severe and it is associated with
a low TR jet velocity of <2 m/s as there is near equalization of
right ventricular and right atrial pressures (9). However, in the
EACVI recommendations, massive TR was defined qualitatively.
There were no quantitative or semi-quantitative parameters that
distinguish massive from severe TR and therein lies a 2-fold
problem. For starter, the distinction between severe and massive
is not always clear. Qualitative parameters such as the size of the
TR jet on color Doppler can change substantially according to
the Nyquist limits and loading conditions. Similarly, in the case
of massive TR with very large regurgitant orifice area, a distinct
color jet may not be apparent due to the presence of laminar,
low velocity flow (10). Also, the use of descriptive terminology
without proper standardization and quantification lacks the
scientific rigor necessary for quality research. Terms such as
very severe, free, massive, or torrential are descriptive and thus
subjected to interpretation. Loose application or interchangeable
usage of these terms are not uncommon both the published
literature and clinical practice, making meaningful, quantitative
comparisons impossible.
“Of note, the EACVI guidelines do not recommend EROA
calculation using the quantitative PW Doppler method due to
the lack of evidence that supports its use in TR quantification.
The quantitative Doppler method however, has been used in
mitral regurgitation studies and it systematically produces a
larger EROA compared to PISA-derived EROA (11). Whether
these findings can be extrapolated in patients with TR and if
the cut-offs for severity grading are comparable warrant further
studies.”
REVISION OF THE CURRENT TR GRADING
SYSTEM
In recent times, there has been a movement to revise the current
TR grading, expanding the TR grading spectrum beyond severe
to include “massive” and “torrential,” in ascending severity (12).
There are a few impetuses to expand the existing guideline-
recommended TR grading. First, the rise of percutaneous
tricuspid valve intervention trials and registry saw the enrolment
of patients with TR far exceeded the severe limit defined by
current guidelines (13). These patients had on average, TR with
VC width, EROA or regurgitant volume one to two grades above
the current definition of severe. Such magnitude calls to question
the adequacy of the current definition at depicting the complete
clinical picture. The lack of further distinction at the extreme
end of the TR spectrum not only leads to non-discriminatory
treatment of TR with different severity and prognosis, but also
makes treatment effect difficult to detect. Natural history studies
have shown that patients’ prognosis worsened as the severity of
TR increases, supporting the case for grading TR beyond severe
to reflect the differential outcomes. This is particularly relevant
among patients who received percutaneous TV interventions.
After all, it is challenging to explain to patients that a therapy
which improves their TR from severe to severe might still benefit
them.
Some percutaneous TR intervention trials that included
sick patients with torrential TR reported improvement in TR
parameters equivalent to one full grade reduction or 20 mm2
in terms of EROA (13, 14). There was also improvement
in measurable clinical outcomes such as New York Heart
Association (NYHA) class, quality of life and 6-min walk test.
Although there was a lack of head-to-head comparison with
patients treated withmedical therapy alone in these trials, it is not
unreasonable to associate these improvements with the reduction
of EROA, reduction in tricuspid annulus size and increase in
forward stroke volume, as a result of the intervention.
In the SCOUT (Percutaneous Tricuspid Valve Annuloplasty
System for Symptomatic Chronic Functional Tricuspid
Regurgitation) trial, the average quantitative EROA of the
cohort was 85 mm2 (13), which is more than 2 grades above the
existing severe threshold of 40 mm2, assuming a grade difference
of 20 mm2. Also, the average vena contracta (VC) of the SCOUT
cohort was 13mm, which is ∼2 grades above the existing severe
threshold of 7mm, assuming a grade difference of 3–4mm.
The transcatheter plication system produced a reduction
of quantitative EROA of >20 mm2, more than a full grade
reduction of TR, which was both statistically significant and
clinically meaningful. In the International Multicentre TriValve
Registry, the average tricuspid EROA was 87 ± 56 mm2 and the
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TABLE 1 | Proposed tricuspid regurgitation grading.
Mild Moderate Severe Massive* Torrential*
QUALITATIVE
TV morphology Normal/abnormal Normal/abnormal Abnormal/flail/large coaptation defect
Color Doppler of TR jet Small, central Intermediate Very large central jet or eccentric wall impinging jet








VC width (mm)§ <3 3–6.9 7–13.9 14–20 >21
PISA radius (mm) ≤5 6–9 >9 — —
Hepatic vein flow Systolic dominance Systolic blunting Systolic flow reversal
Tricuspid inflow Normal Normal E wave dominant (≥1 cm/s)
QUANTITATIVE
EROA (mm2 ) by PISA <20 20–39 40–59 60–79 ≥80
EROA (mm2 ) by quantitative Doppler — — 75–94 95–114 ≥115
EROA (mm2 ) by 3D – – 75–94 95–114 ≥115
R Vol (ml) by PISA <30 30–44 45–59 60–74 ≥75




TABLE 2 | Comparisons of current guideline vs. proposed changes to TR grading.
Proposed TR grading Current guidelines
“Massive” for TR one grade above severe and “torrential” for the most severe
form of TR possible
Made provision for massive TR qualitatively. No clear semi-quantitative or
quantitative definition
Different thresholds for EROA obtained from PISA and quantitative Doppler
methods
No distinction between EROA obtained from PISA and quantitative Doppler
EROAs and regurgitant volumes for massive and torrential TR were defined. Only thresholds for severe (EROA ≥40 mm2 and R Vol ≥45ml) were defined.
Use of 3D vena contracta/effective regurgitant orifice area (the resultant value
should be comparable to EROA obtained from quantitative Doppler)
No mention of 3D assessment
Use of biplane vena contracta Did not emphasise the use of biplane vena contracta
average regurgitant volume was 63ml, while the average VC was
11mm (14), all at 1–2 grades above the current thresholds for
severe TR, defined as EROA of 40 mm2, regurgitant volume of
45ml and VC of 7mm.
The argument for the expansion of the current TR
grading system stems primarily, although not solely, from the
growing need to standardize and quantify transcatheter tricuspid
treatment effect. With no specific criteria that capture the disease
severity at the tail end of the TR spectrum, there is a risk
of diluting measurable treatment effect. Currently, procedural
success is defined as residual TR of ≤2+, successful implantation
of device and patients being alive at the end of the procedure,
similar to the definition used in mitral valve intervention.
Only 62% of patients in the International Multicentre TriValve
Registry achieved procedural success by definition and 51% of
patients still had ≥3+ TR on discharge echocardiography. There
was however, significant improvement in NYHA functional class
and reduction in diuretic requirement at 30 days (14). The
absence of a detailed grading system to quantify treatment effect
may account for the discrepancy between the lack of significant
TR grade reduction and the improvement of quality of life
following successful percutaneous TV intervention.
It is inevitable that an improved TR grading system will
be needed in view of the inadequacy of current definition.
Table 1 illustrates a proposed grading system, with emphasis on a
systematic, multi-parametric approach. Table 2 summarizes the
improvements made in the new grading system compared to
the current guidelines. It must be mentioned that the proposed
TR grading system is based mainly on data gathered from
percutaneous tricuspid intervention studies, which tend to be
modest in study size and highly selective. The grading system
therefore requires further refinement and support from large
natural history, registry or outcome studies.
“In summary, there is no easy solution to the TR grading
conundrum. Perhaps one that come close is to place heavier
emphasis on quantitative assessment of TR. In the context of
tricuspid valve intervention, this can be carried out by routinely
report the EROA before and after the procedure in terms of
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absolute or percentage change. An alternative, as proposed by
Han et al. would be to expand the current grading system linearly
by adding two more grades beyond the current definition of
severe TR. More data, especially long-term outcome data is
needed to resolve the conundrum.”
CONCLUSION
TR has a wide disease spectrum, especially toward the severe end.
A grading approach that emphasize on quantitative assessment
account for the granularity of disease and give equal weightage to
the full disease spectrum. It incorporates our new understanding
of baseline TR severity and make allowance for measurable TR
reduction in the era of percutaneous tricuspid intervention. It
also introduces checks and balances, moving from subjective
definition to a standardized lingo. In the foreseeable future, it is
likely to have an influence on and in turn, be influenced by the
design and evaluation of tricuspid interventional trials.
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